Gastroenterology
Volume 136, Issue 7 , Pages 2092-2100 , June 2009

Budesonide Is Effective in Treating Lymphocytic Colitis: A Randomized Double-Blind Placebo-Controlled Study

  • Stephan Miehlke

      Affiliations

    • Medical Department I, Technical University Hospital, Dresden, Germany
    • Corresponding Author InformationReprint requests Address requests for reprints to: Prof Dr S. Miehlke, Medical Department I, Technical University Hospital, Fetscherstr. 74, 01307 Dresden, Germany. fax: (49) 351 458 5859
    • ,
  • Ahmed Madisch

      Affiliations

    • Medical Department I, Technical University Hospital, Dresden, Germany
    • ,
  • Diana Karimi

      Affiliations

    • Institute for Pathology, Klinikum Bayreuth, Germany
    • ,
  • Susann Wonschik

      Affiliations

    • Medical Department I, Technical University Hospital, Dresden, Germany
    • ,
  • Eberhard Kuhlisch

      Affiliations

    • Institute for Medical Biometry and Statistics, University Hospital Dresden, Dresden, Germany
    • ,
  • Renate Beckmann

      Affiliations

    • Medical Department I, Technical University Hospital, Dresden, Germany
    • ,
  • Andrea Morgner

      Affiliations

    • Medical Department I, Technical University Hospital, Dresden, Germany
    • ,
  • Ralph Mueller

      Affiliations

    • Dr. Falk Pharma GmbH, Freiburg, Germany
    • ,
  • Roland Greinwald

      Affiliations

    • Dr. Falk Pharma GmbH, Freiburg, Germany
    • ,
  • Gerhard Seitz

      Affiliations

    • Institute for Pathology, Klinikum Bamberg, Germany
    • ,
  • Gustavo Baretton

      Affiliations

    • Institute for Pathology, Technical University Hospital Dresden, Germany
    • ,
  • Manfred Stolte

      Affiliations

    • Institute for Pathology, Klinikum Bayreuth, Germany

Received 28 July 2008 ,Accepted 27 February 2009.

References 

  1. Nyhlin N, Bohr J, Eriksson S, Tysk C. Systematic review: microscopic colitis. Aliment Pharmacol Ther. 2006;23:1525–1534
  2. Chande N, Driman DK, Reynolds RPE. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol. 2005;40:343–347
  3. Lazenby AJ. Collagenous and lymphocytic colitis. Semin Diagn Pathol. 2005;22:295–300
  4. Fernandez-Banares F, Esteve M, Espinos JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102:324–330
  5. LaSala PR, Chodosh AB, Vecchio JA, et al. Seasonal pattern of onset in lymphocytic colitis. J Clin Gastroenterol. 2005;39:891–893
  6. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175–181
  7. Madisch A, Bethke B, Stolte M, Miehlke S. Is there an association of microscopic colitis and irritable bowel syndrome - A subgroup analysis of placebo-controlled trials [letter]. World J Gastroenterol. 2005;11:6409
  8. Bonner GF, Petras RE, Cheong DM, et al. Short- and long-term follow-up of treatment for lymphocytic and collagenous colitis. Inflamm Bowel Dis. 2000;6:85–91
  9. Pardi DS, Loftus EV, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56:504–508
  10. Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94:418–423
  11. Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci. 2002;47:1122–1128
  12. Chande N, McDonald WD, MacDonald K. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev. 2007;CD006096
  13. Fine K, Ogunji F, Lee E, et al. Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis [abstract]. Gastroenterology. 1999;116:A880
  14. Wall GC, Schirmer LL, Page MJ. Pharmacotherapy for microscopic colitis. Pharmacotherapy. 2007;27:425–433
  15. Mullhaupt B, Guller U, Anabitarte M, et al. Lymphocytic colitis: clinical presentation and long term course. Gut. 1998;43:629–633
  16. Chande N, McDonald WD, MacDonald K. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2006;(4):CD006096
  17. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology. 2002;122:20–25
  18. Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut. 2003;52:248–251
  19. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002;123:978–984
  20. Mc Keage K, Goa KL. Budesonide (Entocort EC capsules) (A review of its therapeutic use in the management of Crohn's disease in adults). Drugs. 2002;62:2263–2282
  21. Miehlke S, Madisch A, Bethke B, Stolte M. Time to remission with budesonide in collagenous colitis [letter]. Aliment Pharmacol Ther. 2005;21:1507–1508
  22. Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis. 2005;20:312–316
  23. Bullinger M, Kirchberger I, Ware J. Der deutsche SF-36 Health Survey (Übersetzung und psychometrische Testung eines krankheitsübergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualität). Z Gesundheitswissenschaften. 1995;3:21–36
  24. Madisch A, Conrad K, Morgner A, Grossmann D, Rieber EP, Bethke B, et al. The SIBDQ is more suitable than SF-36 to measure improvement of quality of life in patients with collagenous colitis treated with budesonide [abstract]. Gut. 2006;55(Suppl V):A127
  25. Mosnier JF, Larvol L, Barge J, et al. Lymphocytic and collagenous colitis: an immunohistochemical study. Am J Gastroenterol. 1996;91:709–713
  26. Sapp H, Ithamukkala S, Brien TP, et al. The terminal ileum is affected in patients with lymphocytic or collagenous colitis. Am J Surg Pathol. 2002;26:1484–1492
  27. Kolkman JJ, Möllmann HW, Möllmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today. 2004;40:589–601
  28. Herfarth H, Gross V, Andus T, et al. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis. 2004;19:147–152
  29. Fernandez-Bañares F, Esteve M, Salas A, et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci. 2001;46:2231–2238
  30. Bajor A, Kilander A, Gälman C, Rudling M, Ung KA. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment Pharmacol Ther. 2006;24:1643–1649
  31. Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004;53:78–84
  32. Miehlke S, Madisch A, Voss C, et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther. 2005;22:1115–1119

 Conflicts of interest The authors disclose the following: S.M. has received honoraria from Dr Falk Pharma GmbH for oral presentations and consultancies and research grant support from Dr Falk Pharma GmbH. A. Madisch has received honoraria from Dr Falk Pharma GmbH for oral presentations and research grant support from Dr Falk Pharma GmbH. A. Morgner has received honoraria from Dr Falk Pharma GmbH for oral presentations. M.S. has received honoraria from Dr Falk Pharma GmbH for oral presentations and research grant support from Dr Falk Pharma GmbH. R.M. and R.G. are employees of Dr Falk Pharma GmbH. The remaining authors disclose no conflicts.

 Funding The study was supported by Dr Falk Pharma GmbH, Freiburg, Germany.

PII: S0016-5085(09)00365-5

doi: 10.1053/j.gastro.2009.02.078

Gastroenterology
Volume 136, Issue 7 , Pages 2092-2100 , June 2009

Article Tools

* Image Usage & Resolution